Chrona Sleep’s proprietary sleep therapy technology applies acoustic neuromodulation to enhance sleep and neuroplasticity, targeting more than 113 million sleep-deprived Americans. The technology also has clinical implications and could be a disruptive cognitive rehabilitation treatment for PTSD patients. Approximately 15 percent of Veterans in the United States suffer from PTSD, totaling about three million individuals. The sleep device market is expected to experience explosive growth with projections of 248 million devices sold worldwide in 2017 and upwards of one billion in 2020.